News & Updates

Exposure to the Janus kinase (JAK) inhibitors tofacitinib and upadacitinib, as well as to JAK inhibitors as a class, appears to put individuals at increased risk of developing herpes zoster infection, with the risk increasing at higher doses, as reported in a study.

Treatment with rituximab appears to confer protective effects against long-term cardiovascular and metabolic outcomes in patients with pemphigus as compared with conventional immunosuppressants, according to a study.

Use of long-pulsed neodymium-doped yttrium-aluminium-garnet (LP-Nd:YAG) laser provides similar overall therapeutic effects to those of cryotherapy, results of a recent study have shown. However, laser appears more effective against recalcitrant warts and results in shorter time to warts clearance.

New drug applications approved by US FDA as of 16 - 30 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

There appears to be low to no metastatic potential for melanocytic tumours of uncertain malignant potential (MELTUMP) and superficial atypical melanocytic proliferations of uncertain significance (SAMPUS), a recent study has found.